Elisabetta Valentini, Marta Di Martile, Matteo Brignone, Marica Di Caprio, Isabella Manni, Michela Chiappa, Ilaria Sergio, Martina Chiacchiarini, Chiara Bazzichetto, Fabiana Conciatori, Simona D'Aguanno, Carmen D'Angelo, Rino Ragno, Michelangelo Russillo, Gianni Colotti, Francesco Marchesi, Maria Laura Bellone, Fabrizio Dal Piaz, Maria Pia Felli, Giovanna Damia, Donatella Del Bufalo
BH3 mimetics, targeting the Bcl-2 family anti-apoptotic proteins, represent a promising therapeutic opportunity in cancers. ABT-199, the first specific Bcl-2 inhibitor, was approved by FDA for the treatment of several hematological malignancies. We have recently discovered IS21, a novel pan BH3 mimetic with preclinical antitumor activity in several tumor types. Here, we evaluated the efficacy of IS21 and other BH3 mimetics, both as single agents and combined with the currently used antineoplastic agents in T-cell acute lymphoblastic leukemia, ovarian cancer, and melanoma...
July 17, 2023: Cell Death & Disease